CLINICAL_TRIALS
trial_result
· 2016-01-13
Clinical Trial Update: Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population [Phase 4]
Summary
Phase 4 trial update reports progression-free survival results for erlotinib in Chinese patients with non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 4 | Status: COMPLETED | Results posted: 2016-01-13